chartexchange

Leqembi[®] Pen subcutaneous treatment launched in Japan

Cision | Nov 13, 2026 2:00 AM EST

Stockholm, Sweden, November 13, 2026 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi Pen, the subcutaneous formulation of lecanemab, has been launched in Japan for the treatment of early Alzheimer’s disease. Japan is the second country, following the US, where the subcutaneous formulation of Leqembi has been launched.
Leqembi Pen was approved in Japan on September 16, 2026, and has now been included in Japan’s National Health Insurance (NHI) Drug Price List. It is the first and only anti-amyloid treatment in Japan that enables at-home

Read original article